SEC Tracker
Get the app

Amarin AMRN

Amarin reports $39.55M revenue for Q3 2026

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $39.55 million for the three months ended Sep 30, 2026
  2. Net income: $245,000 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $156.51 million at Sep 30, 2026
  4. Diluted EPS: $0.00 for the three months ended Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Amarin files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

4 new legal mentions

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Revenue$39.55M$42.21M−6.3%
Operating income and margin−$2.36M · -6%−$12.01M · -28.5%+80%, margin +22.5 pts
Net income$245K−$7.65M+103%
Operating cash flow$9.22M$6.6M+40%
Cash$156.51M$143.56M+9%
New legal mentions (4)
  • Thereafter, the Company appealed to the Court of Appeals for the Federal Circuit.
  • On October 13, 2026, the parties agreed to a Confidential Settlement Agreement and Release wherein the parties agreed to dismiss all claims for patent infringement with prejudice.
  • On October 13, 2026, the Company and Hikma, in conjunction with the settlement of the patent infringement litigation, further agreed to a Confidential Settlement Agreement and Release wherein in exchange for a negotiated settlement payment, Hikma will voluntarily dismiss with prejudice all pending claims against the…
  • On April 20, 2026, a Stipulation of Voluntary Dismissal of Amarin Defendants with Prejudice was filed in each of the Indirect Purchaser and Direct Purchaser lawsuits. +1 more paragraph

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Rigel Pharmaceuticals RIGL public float $332M, Jun 30, 2025
  2. Northwest Biotherapeutics NWBO public float $340M, Jun 30, 2025
  3. Usana Health Sciences USNA public float $328M, Jun 27, 2025
  4. Emergent BioSolutions EBS public float $343M, Jun 30, 2025
  5. Altimmune ALT public float $327M, Jun 30, 2025